Jim Simons Contrafect Corp Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.19 $31,608 - $66,728	351,200 Added 277.19%	477,900 $46,000
Q3 2022 Nov 14, 2022	BUY	$0.18 - $3.51 $19,098 - $372,411	106,100 Added 515.05%	126,700 $21,000
Q2 2022 Aug 12, 2022	BUY	$2.79 - $4.45 $57,474 - $91,670	20,600 New	20,600 $63,000
Q3 2020 Nov 13, 2020	SELL	$5.05 - $6.99 $630,240 - $872,352	-124,800 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $271,762 - $452,550	57,945 Added 86.67%	124,800 $797,000
Q1 2020 May 14, 2020	BUY	$5.5 - $12.3 $367,702 - $822,316	66,855 New	66,855 $385,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.